SimianX AI LogoSimianX AI

Asset profile

exaluren · Eloxx Pharmaceuticals, Inc. (ELOX)

Indication
nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD)
Also known as
ZKN-013, ELX-02
CompanyELOXEloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to ena…

Start live analysis of ELOXRun 8-agent AI analysis

On the calendar

Timeline

Newest first.

Oct 29, 2026
08:00 PM
ELOXEloxx Pharmaceuticals, Inc.

Eloxx Announces FDA IND Clearance for Exaluren in Nonsense-Mutation ADPKD; EXPRESS Phase 2 First Patient 3Q 2027

OtherCompany press release
Oct 21, 2026
11:31 PM
ELOXEloxx Pharmaceuticals, Inc.

Eloxx Finalizes EXPRESS Phase 2 Design in Nonsense-Mutation ADPKD

Trial registry changeSEC 8-K1 update
Sep 30, 2026
03:21 PM
ELOXEloxx Pharmaceuticals, Inc.

exaluren · NCT07523581 registry update

Trial registry changeClinicalTrials.gov
Aug 11, 2026
09:19 PM
ELOXEloxx Pharmaceuticals, Inc.

Eloxx: EC grants orphan designation for exaluren in ADPKD

FDA designationSEC 8-K

Registered trials

Registry IDPhaseStatusPrimary completionEnrollmentSites
NCT05448755Phase 2CompletedSep 11, 202330 of 4 sites in the United States
NCT04069260Phase 2TerminatedDec 17, 201930 of 1 sites in the United States
NCT04126473Phase 2CompletedApr 6, 2022170 of 9 sites in the United States
NCT07523581Phase 2RecruitingJun 30, 2027247 of 11 sites in the United States
NCT04135495Phase 2CompletedOct 3, 2022177 of 10 sites in the United States
exaluren · Eloxx Pharmaceuticals, Inc. (ELOX) — FDA Timeline & Readiness Checklist | SimianX AI